The general objectives of the REALISE study are to validate the benefits of the FDC through this pragmatic trial in a context of mass drug administration (MDA) programme to evaluate the safety as a primary endpoint and effectiveness profile as a secondary endpoint, in a large population of school-aged children.
The clinical trial will have two arms, randomized by school. One will be administered the fixed-dose coformulation of albendazole and ivermectin while the other, acting as an active control group, will receive
The clinical trial will have two arms, randomized by school. One will be administered a single dose of the fixed-dose coformulation tablet, while the other, acting as an active control group, will receive